


**THE VALUE OF 24 H HEART RATE VARIABILITY IN  
PREDICTING THE MODE OF DEATH IN PATIENTS  
WITH HEART FAILURE AND SYSTOLIC  
DYSFUNCTION IN BETA-BLOCKING ERA**

**Arbolishvili GN, Mareev VY  
Institute of Clinical Cardiology,  
Moscow, Russia**

**ISHNE Heart Failure World-Wide Internet Symposium, 2006**

# Heart Rate Variability (HRV)



**Sympathetic/vagal  
modulation**

**Parasympathetic  
modulation**

## **Objectives:**

**To assess the relationship between parameters of HRV and traditional clinical markers of unfavorable prognosis with total mortality and mode of death in pts with heart failure and LV dysfunction in beta-blocking era.**

## **Inclusion criteria**

- Symptomatic heart failure (NYHA II-IV)**
- Sinus rhythm**
- Left ventricle systolic dysfunction (LVEF  $\leq$  40%)**
- Stable clinical condition**

## Exclusion criteria

- non-sinus rhythm
- myocardial infarction (< 3 months)
- diabetes mellitus
- SA and AV-block
- renal failure
- severe non-cardiac diseases (with poor prognosis)

## Study design

- **Prospective observational study**

## End points

- ❑ Primary endpoint – all-cause mortality
  
- ❑ Secondary endpoints –
  - ❑ pump failure death (PFD)
  - ❑ sudden death (SD)

# Statistical analysis

(stepwise regression analysis)

**Clinical variables**

**Univariable model**

$p < 0.1$

**Multivariable model**

$p < 0.05$

**HRV variables**

**Univariable model**

$p < 0.1$

**Multivariable model**

$p < 0.05$

**Final prognostic model based on forward stepwise  
Cox proportional hazard regression**

$p < 0.05$

**INDEPENDENT PREDICTORS**



# Baseline patients clinical characteristics

Characteristics	Total (n=135)
Age, yrs	52.4 ± 11.9
Gender (m/f)	111/23 (82%/17%)
Etiology (isch/nonisch)	91/43 (68%/32%)
LVEF, %	30.1 ± 6.7
NYHA	2.9 ± 0.8
•NYHA II	56 (42%)
•NYHA III	55 (40%)
•NYHA IV	24 (18%)
VPCs (24h)	219 (34 -817)*
NSVT (n)	57 (35%)

\* Presented as median with 25th and 75th percentiles

# Baseline treatment


Treatment	%
Diuretics	90.3%
ACE Inhibitors	89.1%
Beta-blockers	79.4%
Digoxin	45.1%
Spironolactone	68.6%
Aspirin	76.4%
Nitrates	11.1%
Amiodarone	14.8%
Warfarin	5.6%

# **Heart Rate Variability in Heart Failure**

# HRV measures


Measures	Value
SDNN, ms	107 ± 44.2
SDANN, ms	90.2 ± 29.1
SD, ms	38.1 ± 18.3
RMSDD, ms	28.9 ± 14.8
pNN50, %	3.9 ± 7.4
TP, In ms <sup>2</sup>	9.5 ± 2,5
LF, In ms <sup>2</sup>	5.9 ± 1.2
HF, In ms <sup>2</sup>	5.6 ± 1.4
LF/HF	2.0 ± 1.4
VLF, In ms <sup>2</sup>	7.9 ± 1.4
ULF, In ms <sup>2</sup>	9.8 ± 1.6

# Changes of Heart Rate and SDNN by NYHA



\* p value < 0.05

# Changes of Frequency Domain HRV measures by NYHA




\* p value < 0.05

**TOTAL MORTALITY**

**135 patients**

Follow-up

~2.4 years





## Univariable predictors of total mortality among clinical variables

Variable (cut-off value)	RR	p	95% CI
<b>NYHA, III-IV</b>	<b>3.5</b>	<b>0.003</b>	<b>1.2 - 4.25</b>
<b>NSVT</b>	<b>1.1</b>	<b>0.04</b>	<b>0.2 – 3.4</b>
<b>LVEF <math>\leq</math> 30 %</b>	<b>1.5</b>	<b>0.03</b>	<b>0.8 – 1.7</b>

## Univariable predictors of total mortality among HRV measures

Variable (cut-off value)	RR	p	95% CI
<b>RR <math>\leq</math> 746 ms</b>	<b>1.5</b>	<b>0.01</b>	<b>0.9-1.9</b>
<b>SDNN <math>&lt;</math> 90 ms</b>	<b>3.0</b>	<b>0.0003</b>	<b>1.3 – 4.2</b>
<b>SDANN <math>&lt;</math> 70 ms</b>	<b>1.5</b>	<b>0.006</b>	<b>0.9 – 2.0</b>
<b>TP ln <math>&lt;</math> 9.05 ms<sup>2</sup></b>	<b>1.7</b>	<b>0.002</b>	<b>1.1 – 2.5</b>
<b>LF ln <math>&lt;</math> 5.1 ms<sup>2</sup></b>	<b>1.6</b>	<b>0.005</b>	<b>1.1 – 2.3</b>
<b>VLF ln <math>&lt;</math> 6.35 ms<sup>2</sup></b>	<b>1.3</b>	<b>0.04</b>	<b>0.9 – 2.1</b>
<b>ULF ln <math>&lt;</math> 8.1 ms<sup>2</sup></b>	<b>1.2</b>	<b>0.002</b>	<b>0.8 – 1.6</b>

# Multivariable predictors of total mortality

## *Clinical variables*

Variable (cut-off value)	RR	p	95% CI
<b>NYHA, III-IV</b>	<b>2.0</b>	<b>0.02</b>	<b>1.0 - 3.3</b>


## *HRV measures*

Variable (cut-off value)	RR	p	95% CI
<b>SDNN <math>\leq</math> 90 mc</b>	<b>1.5</b>	<b>0.002</b>	<b>0.6 - 1.8</b>


**Final prognostic multivariable model for  
total mortality  
(forward stepwise Cox proportional hazard  
regression)**

<b>Variable (cut-off value)</b>	<b>RR</b>	<b>p</b>	<b>95% CI</b>
<b>NYHA, III-IV</b>	<b>1.8</b>	<b>0.001</b>	<b>0.7 - 2.8</b>
<b>SDNN <math>\leq</math> 90 ms</b>	<b>1.2</b>	<b>0.002</b>	<b>0.2 - 1.9</b>

# Kaplan-Meier Survival by NYHA



# Kaplan-Meier Survival by SDNN



**PUMP FAILURE DEATH**

# Univariable predictors of pump failure death

<i>Clinical variables</i>			
<b>Variable (cut-off value)</b>	<b>RR</b>	<b>p</b>	<b>95% CI</b>
<b>NYHA, III-IV</b>	<b>9.5</b>	<b>0.0003</b>	<b>2.9 - 16.8</b>
<b>NSVT</b>	<b>1.3</b>	<b>0.003</b>	<b>0.3 – 3.5</b>
<b>LVEF <math>\leq</math> 28 %</b>	<b>1.6</b>	<b>0.02</b>	<b>0.8 – 2.4</b>
<i>HRV measures</i>			
<b>Variable (cut-off value)</b>	<b>RR</b>	<b>p</b>	<b>95% CI</b>
<b>RR <math>\leq</math> 705 <math>\mu</math>c (85')</b>	<b>2.3</b>	<b>0.0004</b>	<b>1.2-3.3</b>
<b>SDNN <math>\leq</math> 85 ms</b>	<b>1.3</b>	<b>0.03</b>	<b>0.7 – 2.2</b>



# Multivariable predictors of pump failure death


<i>Clinical variables</i>			
Variable (cut-off value)	RR	p	95% CI
<b>NYHA, III-IV</b>	<b>8.1</b>	<b>0.001</b>	<b>2.3 - 15.7</b>

<i>HRV measures</i>			
Variable (cut-off value)	RR	p	95% CI
<b>RR <math>\leq</math> 705 ms (85')</b>	<b>2.0</b>	<b>0.001</b>	<b>1.1-3.0</b>


**Final prognostic multivariable model for  
pump failure death  
(forward stepwise Cox proportional hazard  
regression)**

<b>Variable (cut-off value)</b>	<b>RR</b>	<b>p</b>	<b>95% CI</b>
<b>NYHA, III-IV</b>	<b>8.0</b>	<b>0.001</b>	<b>2.1 - 14.8</b>
<b>RR <math>\leq</math> 705 ms (85')</b>	<b>1.5</b>	<b>0.002</b>	<b>0.6 – 3.8</b>


# Kaplan-Meier Survival by NYHA



# Kaplan-Meier Survival by mean RR



# Kaplan-Meier Survival in 2 independent risk factor model



# **SUDDEN DEATH**

# Univariable predictors of sudden cardiac death

<i>Clinical variables</i>			
Variable (cut-off value)	RR	p	95% CI
<b>NYHA, II</b>	<b>6.5</b>	<b>0.0002</b>	<b>2.4 – 9.5</b>
<b>LVEF <math>\leq</math> 26 %</b>	<b>2.4</b>	<b>0.004</b>	<b>1.1 – 3.6</b>

<i>HRV measures</i>			
Variable (cut-off value)	RR	p	95% CI
<b>LF &lt; 4.5, In ms<sup>2</sup></b>	<b>2.1</b>	<b>0.006</b>	<b>0.9 – 5.5</b>
<b>LF/HF &lt; 1.5</b>	<b>3.5</b>	<b>0.001</b>	<b>1.45 – 4.49</b>

## Multivariable predictors of sudden cardiac death

<i>Clinical variables</i>			
<b>Variable (cut-off value)</b>	<b>RR</b>	<b>p</b>	<b>95% CI</b>
<b>NYHA, II</b>	<b>2.0</b>	<b>0.002</b>	<b>1.0 - 3.3</b>
<b>LVEF <math>\leq</math> 26 %</b>	<b>1.1</b>	<b>0,04</b>	<b>0.2 – 4.6</b>




## Multivariable predictors of sudden cardiac death

<i>HRV measures</i>			
<b>Variable (cut-off value)</b>	<b>RR</b>	<b>p</b>	<b>95% CI</b>
<b>LF/HF &lt; 1.5</b>	<b>3.5</b>	<b>0.001</b>	<b>1.45 – 4.49</b>


**Final prognostic multivariable model for sudden cardiac death  
(forward stepwise Cox proportional hazard regression)**

<b>Variable (cut-off value)</b>	<b>RR</b>	<b>p</b>	<b>95% CI</b>
<b>NYHA, II</b>	<b>3.5</b>	<b>0.003</b>	<b>2.0 – 9.5</b>
<b>LVEF <math>\leq</math> 26 %</b>	<b>1.4</b>	<b>0,04</b>	<b>0.4 – 3.0</b>
<b>LF/HF &lt; 1.5</b>	<b>1.5</b>	<b>0.001</b>	<b>0.5 – 2.9</b>

# Kaplan-Meier Survival by LF/HF $\leq 1.5$



# Kaplan-Meier Survival in 3 independent risk factor model



## Conclusions

1. The main HRV indices (both time- and frequency domain) are **depressed** in heart failure which relates to the severity of heart failure
2. **III-IV NYHA** and **SDNN  $\leq$  90 ms** are independent predictors of all-cause mortality.
3. **III-IV NYHA** and mean **RR  $\leq$  705 ms** (HR $\geq$ 85') are independent predictors of death from progressive pump failure. Their combination singles out pts at the most increased risk of pump failure death.

## Conclusions (continued)

5. Patients in **II NYHA**, depressed **LVEF  $\leq 26\%$** , and decreased **LF/HF  $\leq 1.5$**  are independent predictors of sudden death. Their combination singles out patients with heart failure at the most increased risk of sudden death.
6. HRV measures are **advantageous** over traditional markers of unfavorable prognosis (VPCs, NSVT) in identifying patients with heart failure at increased risk of sudden death.